JPWO2020210542A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020210542A5 JPWO2020210542A5 JP2021558847A JP2021558847A JPWO2020210542A5 JP WO2020210542 A5 JPWO2020210542 A5 JP WO2020210542A5 JP 2021558847 A JP2021558847 A JP 2021558847A JP 2021558847 A JP2021558847 A JP 2021558847A JP WO2020210542 A5 JPWO2020210542 A5 JP WO2020210542A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- promoter
- repressor
- pain
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025023769A JP2025084803A (ja) | 2019-04-09 | 2025-02-17 | 標的化されたＩｎ ｖｉｖｏエピジェネティック抑制を介した持続性鎮痛剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962831706P | 2019-04-09 | 2019-04-09 | |
| US62/831,706 | 2019-04-09 | ||
| US201962877810P | 2019-07-23 | 2019-07-23 | |
| US62/877,810 | 2019-07-23 | ||
| PCT/US2020/027541 WO2020210542A1 (en) | 2019-04-09 | 2020-04-09 | Long-lasting analgesia via targeted in vivo epigenetic repression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025023769A Division JP2025084803A (ja) | 2019-04-09 | 2025-02-17 | 標的化されたＩｎ ｖｉｖｏエピジェネティック抑制を介した持続性鎮痛剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022526398A JP2022526398A (ja) | 2022-05-24 |
| JP2022526398A5 JP2022526398A5 (https=) | 2023-02-27 |
| JPWO2020210542A5 true JPWO2020210542A5 (https=) | 2023-02-27 |
Family
ID=72750870
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021558847A Pending JP2022526398A (ja) | 2019-04-09 | 2020-04-09 | 標的化されたＩｎ ｖｉｖｏエピジェネティック抑制を介した持続性鎮痛剤 |
| JP2025023769A Pending JP2025084803A (ja) | 2019-04-09 | 2025-02-17 | 標的化されたＩｎ ｖｉｖｏエピジェネティック抑制を介した持続性鎮痛剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025023769A Pending JP2025084803A (ja) | 2019-04-09 | 2025-02-17 | 標的化されたＩｎ ｖｉｖｏエピジェネティック抑制を介した持続性鎮痛剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220202957A1 (https=) |
| EP (2) | EP4335925A3 (https=) |
| JP (2) | JP2022526398A (https=) |
| KR (1) | KR20210154176A (https=) |
| CN (1) | CN113950526B (https=) |
| CA (1) | CA3131759A1 (https=) |
| WO (1) | WO2020210542A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024505570A (ja) * | 2021-02-01 | 2024-02-06 | ナヴェガ セラピューティクス， インコーポレイテッド | 神経学的疾患及び疼痛を治療するためのエピジェネティック遺伝子調節 |
| US20220325298A1 (en) * | 2021-04-12 | 2022-10-13 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Crispr epigenetic therapeutics for pain management |
| WO2023057880A1 (en) * | 2021-10-05 | 2023-04-13 | Glaxosmithkline Intellectual Property Development Limited | Crispr/cas9-based fusion proteins for modulating gene expression and methods of use |
| WO2023114887A2 (en) * | 2021-12-15 | 2023-06-22 | The Trustees Of Indiana University | Cell targeting compositions and methods |
| CN114317605B (zh) * | 2022-03-11 | 2022-06-21 | 暨南大学 | 一种小胶质细胞钾离子探针转基因小鼠模型的构建方法 |
| KR20240030592A (ko) * | 2022-08-31 | 2024-03-07 | 주식회사 아이엔테라퓨틱스 | 인비보 세포외 신경다발절 기록법을 이용한 전기생리학적 약효평가법 |
| KR20250128349A (ko) * | 2022-12-23 | 2025-08-27 | 에피제닉 테라퓨틱스 피티이 리미티드 | 융합체 및 이의 용도 |
| KR20250124885A (ko) * | 2022-12-23 | 2025-08-20 | 에피제닉 테라퓨틱스 피티이 리미티드 | 복합체 및 이의 용도 |
| WO2025151796A1 (en) * | 2024-01-11 | 2025-07-17 | Regeneron Pharmaceuticals, Inc. | Viral particles retargeted to nervous system tissues |
| WO2025261493A1 (zh) * | 2024-06-21 | 2025-12-26 | 益杰立科(上海)生物科技有限公司 | 通过表观编辑靶向调节pcsk9的方法及其用途 |
| WO2025261475A1 (zh) * | 2024-06-21 | 2025-12-26 | 益杰立科(上海)生物科技有限公司 | 靶向血管内皮生长因子的工程化基因转录阻抑工具及用途 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
| US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
| US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| WO1991017424A1 (en) | 1990-05-03 | 1991-11-14 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
| JP4285766B2 (ja) | 1994-03-23 | 2009-06-24 | オハイオ ユニバーシティ | 緻密にした核酸および細胞へのデリバリ |
| US7013219B2 (en) | 1999-01-12 | 2006-03-14 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| WO2002057294A2 (en) | 2001-01-22 | 2002-07-25 | Sangamo Biosciences, Inc. | Zinc finger proteins for dna binding and gene regulation in plants |
| US20060246440A1 (en) * | 2002-10-23 | 2006-11-02 | Joung J K | Methods for producing zinc finger proteins that bind to extended dna target sequences |
| JP2008506359A (ja) * | 2004-04-08 | 2008-03-06 | サンガモ バイオサイエンシズ インコーポレイテッド | ジンクフィンガータンパク質による神経因性疼痛の処置 |
| KR100756055B1 (ko) * | 2006-01-27 | 2007-09-07 | 연세대학교 산학협력단 | 신생혈관 생성을 조절하는 재조합 아데노바이러스 |
| WO2009033027A2 (en) * | 2007-09-05 | 2009-03-12 | Medtronic, Inc. | Suppression of scn9a gene expression and/or function for the treatment of pain |
| AU2009212247A1 (en) * | 2008-02-08 | 2009-08-13 | Sangamo Therapeutics, Inc. | Treatment of chronic pain with zinc finger proteins |
| US9405700B2 (en) | 2010-11-04 | 2016-08-02 | Sonics, Inc. | Methods and apparatus for virtualization in an integrated circuit |
| CN108285491B (zh) * | 2012-02-29 | 2021-08-10 | 桑格摩生物科学股份有限公司 | 治疗亨廷顿氏病的方法和组合物 |
| DK2931898T3 (en) | 2012-12-12 | 2016-06-20 | Massachusetts Inst Technology | CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS |
| AR095984A1 (es) * | 2013-04-03 | 2015-11-25 | Aliophtha Ag | Factores artificiales de transcripción que regulan receptores nucleares y su uso terapéutico |
| GB2544270A (en) * | 2015-11-05 | 2017-05-17 | Fundació Centre De Regulació Genòmica | Nucleic acids, peptides and methods |
| WO2017083722A1 (en) * | 2015-11-11 | 2017-05-18 | Greenberg Kenneth P | Crispr compositions and methods of using the same for gene therapy |
| SG11201804814YA (en) * | 2015-12-11 | 2018-07-30 | Massachusetts Eye & Ear Infirmary | Materials and methods for delivering nucleic acids to cochlear and vestibular cells |
| AU2017292173B2 (en) * | 2016-07-06 | 2022-01-13 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of pain related disorders |
| KR102547316B1 (ko) * | 2016-08-03 | 2023-06-23 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 아데노신 핵염기 편집제 및 그의 용도 |
| WO2018035503A1 (en) * | 2016-08-18 | 2018-02-22 | The Regents Of The University Of California | Crispr-cas genome engineering via a modular aav delivery system |
| WO2018156824A1 (en) * | 2017-02-23 | 2018-08-30 | President And Fellows Of Harvard College | Methods of genetic modification of a cell |
| EP3592853A1 (en) * | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| US20200255813A1 (en) * | 2017-07-09 | 2020-08-13 | Igc Bio, Inc. | Pross optimized enzymes |
-
2020
- 2020-04-09 US US17/602,150 patent/US20220202957A1/en active Pending
- 2020-04-09 JP JP2021558847A patent/JP2022526398A/ja active Pending
- 2020-04-09 CN CN202080043232.9A patent/CN113950526B/zh active Active
- 2020-04-09 EP EP23211261.5A patent/EP4335925A3/en active Pending
- 2020-04-09 CA CA3131759A patent/CA3131759A1/en active Pending
- 2020-04-09 EP EP20787604.6A patent/EP3953461A4/en not_active Withdrawn
- 2020-04-09 WO PCT/US2020/027541 patent/WO2020210542A1/en not_active Ceased
- 2020-04-09 KR KR1020217036307A patent/KR20210154176A/ko active Pending
-
2025
- 2025-02-17 JP JP2025023769A patent/JP2025084803A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12383587B2 (en) | AAV triple-plasmid system | |
| JP2020522269A5 (https=) | ||
| AU741605B2 (en) | AAV split-packaging genes and cell lines comprising such genes for use in the production of recombinant AAV vectors | |
| US6365403B1 (en) | High-efficiency AAV helper functions | |
| JPWO2020210542A5 (https=) | ||
| JP2024099770A5 (https=) | ||
| JP2021512649A5 (https=) | ||
| US20040209245A1 (en) | Production of pseudotyped recombinant AAV virions | |
| JP2020520643A5 (https=) | ||
| WO1998027204A9 (en) | Aav split-packaging genes and cell lines comprising such genes for use in the production of recombinant aav vectors | |
| JP2021534814A5 (https=) | ||
| IL273394B2 (en) | RNAI variant | |
| JPWO2019153009A5 (https=) | ||
| JPWO2020028816A5 (https=) | ||
| JPWO2020232297A5 (https=) | ||
| JPWO2022023773A5 (https=) | ||
| JPWO2022166954A5 (https=) | ||
| JPWO2022165362A5 (https=) | ||
| JPWO2021222168A5 (https=) | ||
| JPWO2023201274A5 (https=) | ||
| JPWO2022028472A5 (https=) | ||
| JPWO2022016055A5 (https=) | ||
| JPWO2021138559A5 (https=) | ||
| JPWO2020210480A5 (https=) | ||
| JPWO2022060841A5 (https=) |